

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## DCBLD2 RABBIT PAB

货号: S217343 产品全名: DCBLD2 兔多抗 基因符号 ESDN; CLCP1 UNIPROT ID: 096PD2 (Gene Acce

UNIPROT ID: Q96PD2 (Gene Accession - BC029658)

背景: CLCPI (CUB, LCCL and coagulation factor V/VIII-homology domains protein 1), also known as DCBLD2 (discoidin, CUB and LCCL domain containing 2) or ESDN, is a 775 amino acid single-pass type I membrane protein that contains one CUB domain, one LCCL domain and one F5/8 type C domain. Expressed at high levels in heart, testis and skeletal muscle, CLCPI is thought to regulate vascular smooth muscle cell (VSMC) proliferation and remodeling and may be involved in the transformation and metastasis of various cancers, such as metastatic lung cancer and gastric carcinoma.


抗原: Fusion protein of human DCBLD2 经过测试的应用: ELISA, IHC 推荐稀释比: IHC: 100-300; ELISA: 2000-10000 种属反应性: Rabbit 克隆性: Rabbit Polyclonal 亚型: Immunogen-specific rabbit IgG 纯化: Antigen affinity purification

种属反应性: Human, Mouse, Rat


成分: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

研究领域: Signal Transduction, Cardiovascular


储存和运输: Store at -20°C. Avoid repeated freezing and thawing




Immunohistochemistry analysis of paraffin embedded Human gasrtic cancer tissue using 217343(DCBLD2 Antibody) at a dilution of 1/50(Cytoplasm).



In comparision with the IHC on the left, the same paraffin-embedded Human gasrtic cancer tissue is first treated with the fusion protein and then with 217343(Anti-DCBLD2 Antibody) at dilution 1/50.



The image on the left is immunohistochemistry of paraffinembedded Human colon cancer tissue using 217343(Anti-DCBLD2 Antibody) at a dilution of 1/50.



In comparision with the IHC on the left, the same paraffin-embedded Human colon cancer tissue is first treated with fusion protein and then with D222209(Anti-DCBLD2 Antibody) at dilution 1/50.



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010